16 completed, 4 terminated, 2 unknown, 1 recruiting. 13 Phase 2, 11 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 7, Terminated 3, Unknown 2, Recruiting 1 |
| Phase 1 | 11 | Completed 8, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow tetrathiomolybdate: new trials by email Literature Review of tetrathiomolybdate trials Research Report on tetrathiomolybdate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tetrathiomolybdate (TM) Plus Capecitabine Tetrathiomolybdate, Capecitabine, Pembrolizumab - Triple Negative Breast Cancer, Residual Disease | Phase 1 / Phase 2 | Recruiting | Dartmouth-Hitchcock Medical Center | 204 | 2024-11-26 | 2026-04-20 |
| Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Bis-Choline Tetrathiomolybdate - Wilson Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 31 | 2020-12-02 | 2024-10-18 |
| Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants ALXN1840, Bupropion Hydrochloride - Wilson Disease | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 54 | 2020-10-21 | 2023-08-31 |
| A Study of the Cardiac Effects of ALXN1840 in Healthy Adults ALXN1840, Placebo, Moxifloxacin - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 57 | 2020-07-24 | 2023-08-14 |
| Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. ALXN1840, Celecoxib - Wilson Disease | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 36 | 2020-07-07 | 2023-08-21 |
| Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults ALXN1840 - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 48 | 2019-07-04 | 2023-08-02 |
| Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease ALXN1840, SoC Therapy - Wilson Disease | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 214 | 2018-02-22 | 2024-06-17 |
| A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2014-04-07 | 2023-08-02 |
| A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults ALXN1840, Omeprazole - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2014-01-20 | 2023-08-01 |
| Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer Tetrathiomolybdate - Non-Small Cell Lung Cancer | Phase 1 | Completed | University of Rochester | 26 | 2013-11-01 | 2019-07-19 |
| Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer SOD1 inhibitor ATN-224, exemestane, protein expression analysis - Breast Cancer | Phase 2 | Terminated | Cancer Research UK | 111 | 2008-06-01 | 2013-07-10 |
| Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis - Lung Cancer | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2007-05-01 | 2022-10-03 | |
| Study of ATN-224 in Patients With Prostate Cancer ATN-224 - Prostate Cancer | Phase 2 | Unknown | Attenuon | 50 | 2006-11-01 | 2008-01-30 |
| Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma ATN-224, Temozolomide - Melanoma | Phase 2 | Unknown | Attenuon | 60 | 2006-09-01 | 2007-12-06 |
| A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma ATN-224 + bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Attenuon | 46 | 2006-06-01 | 2008-10-28 |
| Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis Tetrathiomolybdate, Placebo - Primary Biliary Cirrhosis | Phase 3 | Completed | George Brewer | 29 | 2006-04-01 | 2017-05-23 |
| A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris Tetrathiomolybdate (TM) - Psoriasis | Phase 2 | Completed | University of Michigan | 10 | 2004-06-01 | 2015-05-21 |
| Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer Tetrathiomolybdate - Breast Cancer | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 16 | 2003-12-01 | 2025-05-16 |
| Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis Tetrathiomolybdate - Idiopathic Pulmonary Fibrosis | Phase 1 / Phase 2 | Completed | University of Michigan | 23 | 2003-03-01 | 2013-02-06 |
| Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma Tetrathiomolybdate (TM), Radiation, Surgery - Esophageal Carcinoma | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 69 | 2001-11-01 | 2016-08-22 |
Showing 20 of 24. Sign in to see all of them.
Hepatolenticular Degeneration (6) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Prostatic Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Idiopathic Pulmonary Fibrosis (1) · Liver Cirrhosis, Biliary (1) · Melanoma (1) · Metabolism, Inborn Errors (1) · Multiple Myeloma (1)
Alexion Pharmaceuticals, Inc. (8) · Attenuon (3) · University of Michigan Rogel Cancer Center (3) · National Center for Research Resources (NCRR) (2) · University of Michigan (2) · Cancer Research UK (1) · Dartmouth-Hitchcock Medical Center (1) · George Brewer (1) · Memorial Sloan Kettering Cancer Center (1) · Roswell Park Cancer Institute (1) · University of Rochester (1)
United States (22) · United Kingdom (4) · Canada (2) · Denmark (2) · New Zealand (2) · Russia (2) · Singapore (2) · Spain (2) · Australia (1) · Austria (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1)
Gilad Gordon, MD (3) · Eugene S. Swenson, MD, PhD (2) · Linda Vahdat, MD (2) · Adrian L. Harris, MD (1) · David C. Smith, MD (1) · David Dougherty, MD (1) · Eugene S. Swenson, M.D., Ph.D. (1) · George J. Brewer (1) · John J Voorhees, MD (1) · Kevin R Flaherty, MD, MS (1) · Mark Zalupski, M.D. (1) · Masood Sadaat, MD, MSc (1) · Mohammad K. Khan, MD, PhD (1) · Susan Urba, M.D. (1)
2019 (2), 2017 (1), M01RR000042 (1), R01CA290013 (1)